Ovarian cancer gene discovery could improve diagnosis
This article was originally published in Clinica
Scientists have identified a genetic mutation that could cause granulosa cell tumours, a type of ovarian cancer. The disorder can be difficult to diagnose, so the discovery "may improve diagnosis in problematic cases and lead to more targeted therapies", the researchers said. They analysed four tumours using whole-transcriptome RNA sequencing, instead of the more conventional method, sequencing genomic DNA. The transcriptome is the full set of protein-encoding mRNA; sequencing the transcriptome is simpler than sequencing the entire genome. The researchers discovered a single, recurrent mutation in the FOXL2 gene, an early marker of ovarian differentiation that is needed for normal granulosa cell development. The findings appeared online in the New England Journal of Medicine on June 10.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.